2010-06-07 23:52:14 - Talecris Biotherapeutics Holdings Corp. (NasdaqGS: TLCR) announced on June 6, 2010 that it agreed to sell the company to Grifols S.A.

Silver Spring, MD - in deal valued at approximately $26.16 per share or $3.4 billion in the aggregate. On the day of the announcement, Talecris disclosed that an affiliate of Cerberus Capital Management entered into a voting agreement under which they have agreed to vote 49% of the Talecris common stock they own in favor of the deal. In the 
most recent quarter, Talecris reported net income of $45.339 million as compared to net income of $1.372 million for the prior quarter. Also, at least one analyst set a price target for Talecris stock at $30.00 per share. Thus far, the shareholders that have weighed in on the deal at BuyoutorSellout.com (buyoutorsellout.com/web/mergers/talecris-biotherapeutics-holding ..) have disapproved of the proposed merger.

BuyoutorSellout.com is the premier destination for shareholders to track merger-related events affecting their investments. The site offers merger-related news, insightful articles and hard-to-find information about merger and acquisition transactions. BuyoutorSellout.com further empowers shareholders by allowing them to voice their opinion about a proposed transaction and let others know how they intend to vote. The opportunity to interact with fellow shareholders allows shareholders to make more educated decisions about the shares you own.